IKTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Inhibikase Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$1.65−0.00 (-0.30%)
Close on Oct 19, 2026
- Market cap
- $287.17M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$0.07 (+4.78%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $287.17M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 1.87
- Dividend yield
- –
- Free cash flow yield
- -14.84%
Fundamentals
- Net income
- -$60.64M
- EPS, diluted
- -$0.44
- Free cash flow
- -$42.61M
- Book value per share
- $0.88
- Diluted shares
- 175M
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Revenue
–
Operating income
-$65.44M
Net income
-$60.64M
EPS, diluted
-$0.44
Free cash flow
-$42.61M
Reported periodTrailing twelve months